| P50 | author | Lucienne Chatenoud | Q15440015 |
| | Jean-François Bach | Q16645214 |
| | Sylvaine You | Q56954682 |
| | Fabrice Valette | Q116996900 |
| P2093 | author name string | Beat Steiner | |
| | Martine Clozel | |
| | Chantal Kuhn | |
| | Luca Piali | |
| | Virginia Sauvaget | |
| P2860 | cites work | Chromogranin A is an autoantigen in type 1 diabetes | Q24605199 |
| | Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis | Q28271008 |
| | Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists | Q29618071 |
| | FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions | Q33283482 |
| | Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs | Q33869799 |
| | Equivalent specificity of peripheral blood and islet-infiltrating CD8+ T lymphocytes in spontaneously diabetic HLA-A2 transgenic NOD mice. | Q51707718 |
| | The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. | Q51769446 |
| | Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. | Q51778586 |
| | Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. | Q53859655 |
| | Induction of allograft tolerance by monoclonal CD3 antibodies: a matter of timing. | Q54297363 |
| | Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. | Q55066037 |
| | FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1-Year, Randomized Controlled Trial in Europe and Australasia | Q63431636 |
| | CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice | Q73128688 |
| | FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation | Q73423109 |
| | Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats | Q73480216 |
| | Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? | Q34099969 |
| | Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice | Q34345367 |
| | Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes | Q34428346 |
| | Oral fingolimod (FTY720) for relapsing multiple sclerosis | Q34565985 |
| | Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. | Q34569888 |
| | Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells | Q34630923 |
| | CD3-specific antibodies: a portal to the treatment of autoimmunity | Q34654024 |
| | A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses | Q34778834 |
| | FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity | Q34786932 |
| | Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice | Q34904815 |
| | Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. | Q35191064 |
| | Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial | Q35321191 |
| | Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment | Q35748567 |
| | Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism | Q36228105 |
| | Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit | Q36402627 |
| | Transforming growth factor-beta and T-cell-mediated immunoregulation in the control of autoimmune diabetes | Q36563528 |
| | Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling | Q36873593 |
| | Finding a way out: lymphocyte egress from lymphoid organs | Q37008187 |
| | Suppressive functions of activated B cells in autoimmune diseases reveal the dual roles of Toll-like receptors in immunity. | Q37700798 |
| | Immune regulatory function of B cells. | Q37973774 |
| | 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. | Q39707090 |
| | Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study | Q42016913 |
| | The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics | Q42521813 |
| | Combined FTY720/cyclosporine A treatment promotes graft survival and lowers the peripheral lymphocyte count in DA to lewis heart and skin transplantation models | Q43584351 |
| | Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. | Q43956895 |
| | Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice | Q44260906 |
| | Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects | Q44854831 |
| | Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. | Q44987202 |
| | Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading | Q45760081 |
| | Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells | Q45858705 |
| | Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen | Q46201877 |
| | Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720. | Q46478164 |
| | Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes | Q46512140 |
| | Detection and characterization of T cells specific for BDC2.5 T cell-stimulating peptides. | Q47564253 |
| | L-selectin(-/lo) and diabetogenic T cells are similarly distributed in prediabetic and diabetic nonobese diabetic mice. | Q48032069 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e77296 | |
| P577 | publication date | 2013-10-24 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes | |
| P478 | volume | 8 | |